The glutaminase inhibitor CB-839 (Telaglenastat) enhances the anti-melanoma activity of T cell mediated immunotherapies.

Immune checkpoint inhibitors and adoptive tumor-infiltrating lymphocyte (TIL) therapies have profoundly improved the survival of melanoma patients. However, a majority of patients do not respond to these agents, and many responders experience disease relapse. While numerous innovative treatments are...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Varghese, Sruthy, Pramanik, Snigdha, Williams, Leila J., Hodges, Hannah R., Hudgens, Courtney W., Fischer, Grant M., Luo, Catherine K., Knighton, Barbara, Tan, Lin, Lorenzi, Philip L., Mackinnon, Andrew L., McQuade, Jennifer L., Hailemichael, Yared, Roszik, Jason, Peng, Weiyi, Vashisht Gopal, Y. N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7933078/
https://ncbi.nlm.nih.gov/pubmed/33361272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0430
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados